Skip to main content
Erschienen in: Journal of Interventional Cardiac Electrophysiology 2/2015

01.03.2015

Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival

verfasst von: Shaan Khurshid, Simon Akerman, Jonathan P. Man, Gregory Supple, Sanjay Dixit, Andrew E. Epstein, Francis E. Marchlinski, David S. Frankel

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Pharmacologic conversion of atrial fibrillation and flutter (AF/AFl) is common with dofetilide. We determined whether pharmacologic conversion with dofetilide predicts long-term arrhythmia-free survival.

Methods

We retrospectively studied a cohort of 264 consecutive patients who initiated dofetilide during persistent AF/AFl between 2008 and 2013. Patients were excluded if dofetilide was discontinued prior to five doses or electrical cardioversion was performed prior to four doses. Incidence of and characteristics associated with pharmacologic conversion were determined. Patients were followed for long-term AF/AFl recurrence. Predictors of recurrence were identified using multivariate Cox modeling.

Results

Of 205 patients meeting study criteria, 92 (44.9 %) converted to sinus rhythm during dofetilide loading. Female gender, history of AFl, greater number of prior catheter ablations, shorter duration of current AF/AFl, and presentation in AFl were all associated with acute pharmacologic conversion (p = 0.001, 0.05, 0.001, 0.003, and 0.003, respectively). In multivariate modeling, longer time since first AF/AFl diagnosis (hazard ratio (HR) = 1.07 per 1-year increase, 95 % confidence interval (CI) 1.03–1.10, p < 0.001), longer duration of current AF/AFl episode (HR = 1.01 per 1-month increase, 95 % CI 1.00–1.01, p = 0.003) and greater number of failed antiarrhythmic drugs (HR = 1.43 per one drug increase, 95 % CI 1.20–1.70, p < 0.001) were independently associated with shorter time to AF/AFl recurrence. Pharmacologic conversion was not significantly associated with time to AF/AFl recurrence (HR = 0.79, 95 % CI 0.57–1.10, p = 0.2).

Conclusions

Acute pharmacologic conversion of persistent AF/AFl to sinus rhythm frequently occurs during dofetilide loading. Nevertheless, acute pharmacologic conversion does not predict long-term arrhythmia control, which was moderate at best.
Literatur
1.
Zurück zum Zitat Corley, S. D., Epstein, A. E., DiMarco, J. P., Domanski, M. J., Geller, N., Greene, H. L., et al. (2004). Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation, 109(12), 1509–1513.CrossRefPubMed Corley, S. D., Epstein, A. E., DiMarco, J. P., Domanski, M. J., Geller, N., Greene, H. L., et al. (2004). Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation, 109(12), 1509–1513.CrossRefPubMed
2.
Zurück zum Zitat Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. (2002). A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. The American Journal of Medicine, 113(5), 359–364.CrossRefPubMed Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. (2002). A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. The American Journal of Medicine, 113(5), 359–364.CrossRefPubMed
3.
Zurück zum Zitat Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1987). Atrial fibrillation: a major contributor to stroke in the elderly. the Framingham Study. Archives of Internal Medicine, 147(9), 1561–1564.CrossRefPubMed Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1987). Atrial fibrillation: a major contributor to stroke in the elderly. the Framingham Study. Archives of Internal Medicine, 147(9), 1561–1564.CrossRefPubMed
4.
Zurück zum Zitat Baman, T. S., Ilg, K. J., Gupta, S. K., Good, E., Chugh, A., Jongnarangsin, K., et al. (2010). Mapping and ablation of epicardial idiopathic ventricular arrhythmias from within the coronary venous system. Circulation. Arrhythmia and Electrophysiology, 3(3), 274–279.CrossRefPubMed Baman, T. S., Ilg, K. J., Gupta, S. K., Good, E., Chugh, A., Jongnarangsin, K., et al. (2010). Mapping and ablation of epicardial idiopathic ventricular arrhythmias from within the coronary venous system. Circulation. Arrhythmia and Electrophysiology, 3(3), 274–279.CrossRefPubMed
5.
Zurück zum Zitat Savelieva, I., & Camm, J. (2008). Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace, 10(6), 647–665.CrossRefPubMed Savelieva, I., & Camm, J. (2008). Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace, 10(6), 647–665.CrossRefPubMed
6.
Zurück zum Zitat Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., et al. (2005). Amiodarone versus sotalol for atrial fibrillation. The New England Journal of Medicine, 352(18), 1861–1872.CrossRefPubMed Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., et al. (2005). Amiodarone versus sotalol for atrial fibrillation. The New England Journal of Medicine, 352(18), 1861–1872.CrossRefPubMed
7.
Zurück zum Zitat Singh, S., Zoble, R. G., Yellen, L., Brodsky, M. A., Feld, G. K., Berk, M., et al. (2000). Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation, 102(19), 2385–2390.CrossRefPubMed Singh, S., Zoble, R. G., Yellen, L., Brodsky, M. A., Feld, G. K., Berk, M., et al. (2000). Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation, 102(19), 2385–2390.CrossRefPubMed
8.
Zurück zum Zitat Pedersen, O. D., Bagger, H., Keller, N., Marchant, B., Kober, L., & Torp-Pedersen, C. (2001). Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation, 104(3), 292–296.CrossRefPubMed Pedersen, O. D., Bagger, H., Keller, N., Marchant, B., Kober, L., & Torp-Pedersen, C. (2001). Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation, 104(3), 292–296.CrossRefPubMed
9.
Zurück zum Zitat Banchs, J. E., Wolbrette, D. L., Samii, S. M., Penny-Peterson, E. D., Patel, P. P., Young, S. K., et al. (2008). Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter. Journal of Interventional Cardiac Electrophysiology, 23(2), 111–115.CrossRefPubMed Banchs, J. E., Wolbrette, D. L., Samii, S. M., Penny-Peterson, E. D., Patel, P. P., Young, S. K., et al. (2008). Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter. Journal of Interventional Cardiac Electrophysiology, 23(2), 111–115.CrossRefPubMed
10.
Zurück zum Zitat Cotiga, D., Arshad, A., Aziz, E., Joshi, S., Koneru, J. N., & Steinberg, J. S. (2007). Acute conversion of persistent atrial fibrillation during dofetilide initiation. Pacing and Clinical Electrophysiology : PACE, 30(12), 1527–1530.CrossRefPubMed Cotiga, D., Arshad, A., Aziz, E., Joshi, S., Koneru, J. N., & Steinberg, J. S. (2007). Acute conversion of persistent atrial fibrillation during dofetilide initiation. Pacing and Clinical Electrophysiology : PACE, 30(12), 1527–1530.CrossRefPubMed
11.
Zurück zum Zitat Prystowsky, E. N., Freeland, S., Branyas, N. A., Rardon, D. P., Fogel, R. I., Padanilam, B. J., et al. (2003). Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology, 14(12 Suppl), S287–S290.CrossRefPubMed Prystowsky, E. N., Freeland, S., Branyas, N. A., Rardon, D. P., Fogel, R. I., Padanilam, B. J., et al. (2003). Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology, 14(12 Suppl), S287–S290.CrossRefPubMed
12.
Zurück zum Zitat Calkins, H., Kuck, K. H., Cappato, R., Brugada, J., Camm, A. J., Chen, S. A., et al. (2012). 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm, 9(4), 632–696. e621.CrossRefPubMed Calkins, H., Kuck, K. H., Cappato, R., Brugada, J., Camm, A. J., Chen, S. A., et al. (2012). 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm, 9(4), 632–696. e621.CrossRefPubMed
14.
Zurück zum Zitat Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001). Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA, 285(22), 2864–2870.CrossRefPubMed Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001). Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA, 285(22), 2864–2870.CrossRefPubMed
15.
Zurück zum Zitat Borgeat, A., Goy, J. J., Maendly, R., Kaufmann, U., Grbic, M., & Sigwart, U. (1986). Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. The American Journal of Cardiology, 58(6), 496–498.CrossRefPubMed Borgeat, A., Goy, J. J., Maendly, R., Kaufmann, U., Grbic, M., & Sigwart, U. (1986). Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. The American Journal of Cardiology, 58(6), 496–498.CrossRefPubMed
16.
Zurück zum Zitat Bianconi, L., Mennuni, M., Lukic, V., Castro, A., Chieffi, M., & Santini, M. (1996). Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. Journal of the American College of Cardiology, 28(3), 700–706.CrossRefPubMed Bianconi, L., Mennuni, M., Lukic, V., Castro, A., Chieffi, M., & Santini, M. (1996). Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. Journal of the American College of Cardiology, 28(3), 700–706.CrossRefPubMed
17.
Zurück zum Zitat Di Benedetto, S. (1997). Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm. The American Journal of Cardiology, 80(4), 518–519.CrossRefPubMed Di Benedetto, S. (1997). Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm. The American Journal of Cardiology, 80(4), 518–519.CrossRefPubMed
18.
Zurück zum Zitat Kochiadakis, G. E., Igoumenidis, N. E., Solomou, M. C., Kaleboubas, M. D., Chlouverakis, G. I., & Vardas, P. E. (1999). Efficacy of amiodarone for the termination of persistent atrial fibrillation. The American Journal of Cardiology, 83(1), 58–61.CrossRefPubMed Kochiadakis, G. E., Igoumenidis, N. E., Solomou, M. C., Kaleboubas, M. D., Chlouverakis, G. I., & Vardas, P. E. (1999). Efficacy of amiodarone for the termination of persistent atrial fibrillation. The American Journal of Cardiology, 83(1), 58–61.CrossRefPubMed
19.
Zurück zum Zitat Kerin, N. Z., Faitel, K., & Naini, M. (1996). The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. Archives of Internal Medicine, 156(1), 49–53.CrossRefPubMed Kerin, N. Z., Faitel, K., & Naini, M. (1996). The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. Archives of Internal Medicine, 156(1), 49–53.CrossRefPubMed
20.
Zurück zum Zitat Tieleman, R. G., Gosselink, A. T., Crijns, H. J., van Gelder, I. C., van den Berg, M. P., de Kam, P. J., et al. (1997). Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. The American Journal of Cardiology, 79(1), 53–57.CrossRefPubMed Tieleman, R. G., Gosselink, A. T., Crijns, H. J., van Gelder, I. C., van den Berg, M. P., de Kam, P. J., et al. (1997). Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. The American Journal of Cardiology, 79(1), 53–57.CrossRefPubMed
21.
Zurück zum Zitat Singh, S., Saini, R. K., DiMarco, J., Kluger, J., Gold, R., & Chen, Y. W. (1991). Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group. The American Journal of Cardiology, 68(11), 1227–1230.CrossRefPubMed Singh, S., Saini, R. K., DiMarco, J., Kluger, J., Gold, R., & Chen, Y. W. (1991). Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group. The American Journal of Cardiology, 68(11), 1227–1230.CrossRefPubMed
22.
Zurück zum Zitat Hohnloser, S. H., van de Loo, A., & Baedeker, F. (1995). Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Journal of the American College of Cardiology, 26(4), 852–858.CrossRefPubMed Hohnloser, S. H., van de Loo, A., & Baedeker, F. (1995). Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Journal of the American College of Cardiology, 26(4), 852–858.CrossRefPubMed
23.
Zurück zum Zitat Crijns, H. J., Van Gelder, I. C., Van Gilst, W. H., Hillege, H., Gosselink, A. M., & Lie, K. I. (1991). Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. The American Journal of Cardiology, 68(4), 335–341.CrossRefPubMed Crijns, H. J., Van Gelder, I. C., Van Gilst, W. H., Hillege, H., Gosselink, A. M., & Lie, K. I. (1991). Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. The American Journal of Cardiology, 68(4), 335–341.CrossRefPubMed
24.
Zurück zum Zitat Crijns, H. J., Gosselink, A. T., & Lie, K. I. (1996). Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. Cardiovascular Drugs and Therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy, 10(2), 145–152.CrossRefPubMed Crijns, H. J., Gosselink, A. T., & Lie, K. I. (1996). Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. Cardiovascular Drugs and Therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy, 10(2), 145–152.CrossRefPubMed
25.
Zurück zum Zitat Le Heuzey, J. Y., De Ferrari, G. M., Radzik, D., Santini, M., Zhu, J., & Davy, J. M. (2010). A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of Cardiovascular Electrophysiology, 21(6), 597–605.CrossRefPubMed Le Heuzey, J. Y., De Ferrari, G. M., Radzik, D., Santini, M., Zhu, J., & Davy, J. M. (2010). A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of Cardiovascular Electrophysiology, 21(6), 597–605.CrossRefPubMed
26.
Zurück zum Zitat Pamukcu, B., & Lip, G. Y. (2010). Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study. Expert Opinion on Pharmacotherapy, 11(17), 2775–2778.CrossRefPubMed Pamukcu, B., & Lip, G. Y. (2010). Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study. Expert Opinion on Pharmacotherapy, 11(17), 2775–2778.CrossRefPubMed
27.
Zurück zum Zitat Feld, G. K., & Cha, Y. (1997). Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide in an experimental canine model of pacing-induced atrial fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 2(3), 195–203.CrossRefPubMed Feld, G. K., & Cha, Y. (1997). Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide in an experimental canine model of pacing-induced atrial fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 2(3), 195–203.CrossRefPubMed
28.
Zurück zum Zitat Malhotra, R., Bilchick, K. C., & DiMarco, J. P. (2014). Usefulness of pharmacologic conversion of atrial fibrillation during dofetilide loading without the need for electrical cardioversion to predict durable response to therapy. The American Journal of Cardiology, 113(3), 475–479.CrossRefPubMedCentralPubMed Malhotra, R., Bilchick, K. C., & DiMarco, J. P. (2014). Usefulness of pharmacologic conversion of atrial fibrillation during dofetilide loading without the need for electrical cardioversion to predict durable response to therapy. The American Journal of Cardiology, 113(3), 475–479.CrossRefPubMedCentralPubMed
29.
Zurück zum Zitat Wijffels, M. C., Kirchhof, C. J., Dorland, R., & Allessie, M. A. (1995). Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation, 92(7), 1954–1968.CrossRefPubMed Wijffels, M. C., Kirchhof, C. J., Dorland, R., & Allessie, M. A. (1995). Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation, 92(7), 1954–1968.CrossRefPubMed
30.
Zurück zum Zitat Morillo, C. A., Klein, G. J., Jones, D. L., & Guiraudon, C. M. (1995). Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation, 91(5), 1588–1595.CrossRefPubMed Morillo, C. A., Klein, G. J., Jones, D. L., & Guiraudon, C. M. (1995). Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation, 91(5), 1588–1595.CrossRefPubMed
31.
Zurück zum Zitat Manning, W. J., Silverman, D. I., Katz, S. E., Riley, M. F., Come, P. C., Doherty, R. M., et al. (1994). Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. Journal of the American College of Cardiology, 23(7), 1535–1540.CrossRefPubMed Manning, W. J., Silverman, D. I., Katz, S. E., Riley, M. F., Come, P. C., Doherty, R. M., et al. (1994). Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. Journal of the American College of Cardiology, 23(7), 1535–1540.CrossRefPubMed
32.
Zurück zum Zitat Frustaci, A., Chimenti, C., Bellocci, F., Morgante, E., Russo, M. A., & Maseri, A. (1997). Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 96(4), 1180–1184.CrossRefPubMed Frustaci, A., Chimenti, C., Bellocci, F., Morgante, E., Russo, M. A., & Maseri, A. (1997). Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 96(4), 1180–1184.CrossRefPubMed
33.
Zurück zum Zitat Allessie, M., Ausma, J., & Schotten, U. (2002). Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovascular Research, 54(2), 230–246.CrossRefPubMed Allessie, M., Ausma, J., & Schotten, U. (2002). Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovascular Research, 54(2), 230–246.CrossRefPubMed
34.
Zurück zum Zitat Everett, T. H., Wilson, E. E., Verheule, S., Guerra, J. M., Foreman, S., & Olgin, J. E. (2006). Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling. American Journal of Physiology. Heart and Circulatory Physiology, 291(6), H2911–H2923.CrossRefPubMedCentralPubMed Everett, T. H., Wilson, E. E., Verheule, S., Guerra, J. M., Foreman, S., & Olgin, J. E. (2006). Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling. American Journal of Physiology. Heart and Circulatory Physiology, 291(6), H2911–H2923.CrossRefPubMedCentralPubMed
Metadaten
Titel
Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival
verfasst von
Shaan Khurshid
Simon Akerman
Jonathan P. Man
Gregory Supple
Sanjay Dixit
Andrew E. Epstein
Francis E. Marchlinski
David S. Frankel
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 2/2015
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-015-9974-7

Weitere Artikel der Ausgabe 2/2015

Journal of Interventional Cardiac Electrophysiology 2/2015 Zur Ausgabe

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.